BioIVT, a leading provider of biospecimens and ADME-Tox research products and services for drug and diagnostic development, today announced that it will be showcasing its expanded ADME-Tox portfolio at the 16th European ISSX and DMDG Meeting, which will be held from June 11-14 at the University of Hertfordshire in the UK.
“We’re looking forward to meeting with our research colleagues at ISSX. This is the first major conference at which we’ll be presenting our new integrated service portfolio since XenoTech joined BioIVT. We’re excited to be able to demonstrate how our expanded offerings enable us to be even more effective at helping our clients advance their drug R&D programs,” said Dr. Christopher Black, BioIVT Senior Vice President ADME-Tox. “We now have the capabilities and capacity to design and implement all types of ADME studies in addition to being the leading supplier of hepatocytes and related hepatic products.”
“ISSX events are a highlight of our year because they are amongst the best scientific conferences at which to discuss new in vitro ADME study methodologies,” said Dr. Joanna Barbara, Site Lead at BioIVT’s laboratory in Kansas City. “I am privileged to be able to kick things off on Monday morning with our symposium on accounting for complications like protein binding and drug instability in drug transporter studies and beyond, and I am looking forward to engaging with industry colleagues on this topic and many more.”
Dr. Barbara’s symposium entitled “Uncooperative drugs in in vitro transporter research: Practical approaches to address instability and nonspecific binding challenges” will take place from 7:15-8:15 am on June 12. She will present in vitro drug transporter case studies which demonstrate creative solutions for determining a compound’s drug-drug interaction potential even if the product is unstable, sticky, or insoluble, and initially produces convoluted or inconclusive results.
BioIVT and XenoTech ADME-Tox experts will also be available to answer technical questions in booth #18. Additional information about BioIVT’s comprehensive ADME products and services can be found at www.bioivt.com.
Further details about this conference are available at https://issx2023.org/issx-dmdg/meeting-program.
BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to the life science and diagnostic industries. Recognized as an industry leader, BioIVT specializes in control and disease state samples including human and animal tissues or preparations, ADME-Tox products and research services, cell and gene therapy products, blood, and other biofluids. By combining technical expertise and exceptional customer service with unmatched access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.